Bydureon, the experimental type 2 diabetes drug from Amylin Pharmaceuticals, Eli Lilly and Co. and Alkermes, can improve cardiovascular health better than existing therapies, according to new data.
The companies said results of the "DURATION-3" and "DURATION-4" trials showed that patients treated with Bydureon (exenatide) experienced a reduction in cardiovascular health risk factors such as body weight, blood pressure and lipid levels.
Bydureon is a long-acting formulation of the widely used, injectable drug treatment Byetta.
Patients in the DURATION-3 study received either Bydureon or Sanofi's Lantus as well as metformin, or metformin with sulfonylurea - both widely used generic treatments for diabetes .
In the DURATION-4 trial, patients received Bydureon, metformin, Takeda's Actos (pioglitazone) or Merck and Co.'s Januvia (sitagliptin).
Patients treated with Bydureon in both trials showed better blood pressure reduction and weight control than those taking the other diabetes medications .
The results were presented at the 47th European Association for the Study of Diabetes (EASD) 2011 Annual Meeting in Lisbon, Portugal.
Bydureon Diabetes Drug Trials Show Cardiovascular Health Benefits
Tue, 13 Sep 2011
Recommended links
Diabetes IndiaDiabetes guides, tools and news
Diabetes symptoms
Diabetes complications
Diabetes treatments
Medications for Type 2 diabetes
Diabetes self help measures
Body Mass Index (BMI) calculator
500,00 Diabetics In England At Risk Of Blindness
Novo Nordisk Rolls Out Childhood Diabetes Care Campaign In India
Replacing White Rice With Beans Lowers Diabetes Risk
Scientists Highlight Five Key Lifestyle Factors For Diabetes Prevention
Yoga Shows Some Benefit For Diabetes
Electronic Health Records Linked To Better Diabetes Care
Vascular Health Checks
